D-0437-2024 Class II Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-0437-2024 was initiated by Lupin Pharmaceuticals Inc. on Mar 21, 2024 and is designated Class II. Reason for recall: Subpotent Drug The recall status is terminated (terminated Apr 4, 2025). Affected quantity: 26,352 bottles.

Recall Details

Product Type
Drugs
Report Date
Apr 17, 2024
Initiation Date
Mar 21, 2024
Termination Date
Apr 4, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
26,352 bottles

Product Description

Rifampin Capsules USP, 300mg, 30-count bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad 431 210 India, NDC 6818-0659-06

Reason for Recall

Subpotent Drug

Distribution Pattern

Nationwide within the United States

Code Information

Lot #: A201064, Exp. Date March 2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0437-2024
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0437-2024. Report a data issue: hello@regdatalab.com.